After clinical trials demonstrated its efficacy and safety, the FDA has approved a new treatment option for patients with chronic hepatitis C virus without cirrhosis or with mild cirrhosis.
After clinical trials demonstrated its efficacy and safety, the FDA has approved a new treatment option for patients with chronic hepatitis C virus without cirrhosis or with mild cirrhosis.
After clinical trials demonstrated its efficacy and safety, the FDA has approved a new treatment option for patients with chronic hepatitis C virus without cirrhosis or with mild cirrhosis.
The US Food and Drug Administration recently approved a new treatment option for patients with early stage HER2-overexpressed/amplified breast cancer. For recommended dosage and common adverse events, read...
The US Food and Drug Administration recently approved a new treatment option for patients with early stage HER2-overexpressed/amplified breast cancer. For recommended dosage and common adverse events, read...
The US Food and Drug Administration recently approved a new treatment option for patients with early stage HER2-overexpressed/amplified breast cancer. For recommended dosage and common adverse events, read...
After clinical trials demonstrated its efficacy, the US Food and Drug Administration approved a biologic therapy for the treatment of patients with moderate to severe plaque psoriasis.
After clinical trials demonstrated its efficacy, the US Food and Drug Administration approved a biologic therapy for the treatment of patients with moderate to severe plaque psoriasis.
